The Government of India has granted approval for 41 projects under the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), amounting to approximately Rs 1,600 crore in financial assistance. This initiative aims to foster innovation and research in the pharmaceutical and medical technology sectors.

The approved projects are expected to stimulate an additional Rs 3,020 crore in private investment, thereby bringing the total research and development investment associated with these initiatives to around Rs 4,620 crore. This significant funding is aimed at enhancing the innovation landscape in the pharmaceutical sector.

The projects encompass a broad spectrum of the innovation value chain, including novel drug discovery, clinical development, and the creation of innovative medical technologies. This multifaceted approach is anticipated to generate substantial advancements in the fields concerned.

Project Overview and Distribution

The projects focus on several priority areas within the sector, with 27 pertaining to New Medicines, five targeting Complex Generics and Biosimilars, and nine related to Novel Medical Devices. This distribution reflects a comprehensive approach to addressing various critical health needs in the market.

Key participants in this endeavour include notable companies like Biocon, Bharat Biotech, Sun Pharma, Wockhardt, Zydus, Mankind Pharma, Pandorum Technologies, Cellogen Therapeutics, Aurigene Oncology, and Bugworks Research. These established entities are instrumental in fostering innovation by leveraging their extensive experience and resources.

Focus on Innovative Health Solutions

The initiatives being supported by the PRIP highlight a shift away from a volume-driven pharmaceutical model towards an approach that prioritises innovation and technology. These projects encompass first-in-class innovations and emerging technologies that are poised for global market integration, addressing significant public health challenges.

Noteworthy projects include an antibacterial treatment aimed at combating multidrug-resistant Gram-negative infections, an exosome-based regenerative therapy targeting corneal disease, and patient-derived breast cancer organoids. Additional innovations involve developing a programmable RNA-targeting antiviral technology along with portable diagnostic solutions.

Under a strategic framework for priority innovations, six projects have received enhanced support for addressing areas such as neglected tropical diseases, rare diseases, and antimicrobial resistance, particularly concerning pathogens recognised as high priorities for India. These include initiatives related to bacterial pneumonia, meningitis, dengue, and next-generation vaccines for tuberculosis.

The evaluation process for the remaining applications submitted under the first round of PRIP is ongoing, with further announcements expected over the next month. This forthcoming information may provide additional insights into the innovations that will receive support in this significant funding round.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share